Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Peng Liu
CONTACT
Lead
Shanghai Zhongshan Hospital
With
This study is a prospective, single-center, interventional, phase 2 study. Each patient screend eligible for this study will receive a combination therapy of glofitamab, zanubrutinib and polatuzumab vedotin.
Age
70–any
Sex
ALL
Healthy volunteers
Not accepted